What happened with ALEC today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Alector is a clinical-stage biotechnology company working on treatments for diseases such as Alzheimer’s and Parkinson’s. Its clinical candidate, nivisnebart, is an antibody intended to raise progranulin levels and is in a Phase 2 trial for early Alzheimer’s disease with GSK. Alector also owns earlier-stage research programs. It has no approved drugs and earns no revenue from product sales.
GSK is its key revenue partner. GSK has paid Alector upfront for their collaboration, and further payments depend on development, regulatory and commercial milestones. The companies share development costs. If a collaborating drug reaches the market, Alector would share its U.S. profits and losses with GSK and receive royalties on sales elsewhere, where GSK handles commercialization.
Alector stopped developing latozinemab after it failed a late-stage trial, leaving nivisnebart as its sole clinical-stage candidate. The business depends on that program’s progress, GSK’s continued participation and additional funding for research and development. Alector also relies on GSK and outside manufacturers for drug supplies. Product sales cannot begin unless candidates complete further development and obtain regulatory approval.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Roche, absent from this list, is another important rival in neurodegenerative treatments and brain delivery to watch as Alector’s prospects depend on clinical success and its GSK collaboration.
Alector depends on GSK to co-develop its progranulin-raising antibodies, share development costs and pay potential milestones, with equal US profit-and-loss sharing and royalties on sales outside the US. Watch GSK’s nivisnebart trial in early Alzheimer’s disease: it directly tests a clinical-stage program in Alector’s portfolio.
Denali Therapeutics competes with Alector both in Alzheimer’s treatments and in carrying drugs across the brain’s protective barrier. Watch its amyloid-beta and tau programs for evidence that its delivery technology can distribute treatments through the brain; the reported delivery findings are still preclinical.
Prothena competes with Alector in Alzheimer’s and Parkinson’s drug development, including research on Alzheimer’s treatments designed to enter the brain. Its preclinical PRX012-TfR Alzheimer’s program is the closest overlap to watch alongside its clinical Parkinson’s program, prasinezumab.
Biogen’s Leqembi already competes for the Alzheimer’s patients Alector hopes to treat with drugs intended to change the disease’s course. Leqembi’s efficacy, safety and ease of administration are therefore more relevant to Alector than Biogen’s broader medicines business.
Eli Lilly’s Kisunla sets an existing efficacy and safety benchmark for Alector’s investigational Alzheimer’s treatments. Watch Kisunla’s treatment results rather than Lilly’s overall drug sales when judging what Alector’s candidates would need to offer patients.
Acumen Pharmaceuticals’ sabirnetug competes with Alector’s anti-amyloid antibody research in seeking to change Alzheimer’s disease rather than just relieve symptoms. Watch sabirnetug’s efficacy and safety: Acumen had no approved products or product-sales revenue through fiscal 2025, so this is a development comparison, not a sales comparison.
Voyager Therapeutics challenges Alector in Alzheimer’s and Parkinson’s development and in getting treatments across the brain’s protective barrier. Its TRACER platform uses engineered virus shells to carry gene therapies into the brain after intravenous dosing, offering a different delivery approach from Alector’s antibody-based ABC platform.
AC Immune competes with Alector on immune-based Alzheimer’s treatments directed at disease-linked proteins. Its approach prompts patients to make their own antibodies against abnormal protein forms, while pharmaceutical partners help fund and develop selected candidates.
ProMIS Neurosciences competes with Alector in developing antibodies against harmful proteins in Alzheimer’s and other neurodegenerative diseases. Watch whether its antibodies can target toxic, misfolded proteins without disturbing healthy forms—the intended distinction behind its amyloid-beta, tau and alpha-synuclein programs.
Cognition Therapeutics offers a competing route to treating Alzheimer’s underlying pathology: small-molecule drugs rather than Alector’s antibody and nucleic-acid approaches. Watch clinical progress with zervimesine; Cognition does not expect product-sales revenue until a candidate completes development and gains approval.
Annovis Bio’s buntanetap competes with Alector’s programs in trying to change neurodegenerative disease by addressing harmful proteins rather than symptoms alone. Annovis says buntanetap is designed to reduce production of several neurotoxic proteins; clinical evidence for that intended effect matters more than sales, which it had not generated through December 31, 2025.
Anavex Life Sciences competes with Alector in seeking disease-modifying Alzheimer’s and Parkinson’s treatments, with both using biological markers to guide development. Watch whether ANAVEX2-73 studies support identifying patients more likely to respond through genetic variants such as SIGMAR1; that is the specific patient-selection approach Anavex is exploring.
Biogen Inc. earningsBIIB
Biogen’s report can show how Leqembi is being used by people with Alzheimer’s, revealing the established competition Alector’s candidates must face.
Look for evidence of Leqembi’s use and what Biogen says about its efficacy, safety, and administration. Continued use without major treatment barriers would mean Alector’s future Alzheimer’s drugs must show a meaningful difference in benefit or convenience; limits tied to safety or administration would weaken the established treatment’s reach, but would not establish that Alector’s candidates work.
Fed Interest Rate Decision
Alector’s Fed rate decision matters because its floating-rate term loan can make borrowing from lenders more or less costly.
Expected4.0%Last release4.0%
If it comes in above expectations
A higher-than-expected policy rate can raise the interest Alector pays on its loan, leaving less cash for research and development.
If it comes in below expectations
A lower-than-expected policy rate can reduce the interest Alector pays on its loan, leaving more cash for research and development.
Alector, Inc. earningsThis company
Alector has no approved-drug sales, so its report shows how collaboration revenue and research spending shape the cash available to advance its drug candidates.
Read collaboration revenue alongside research and development spending and cash used in operations, then check the cash and marketable securities balance. Lower spending and cash use while the nivisnebart trial advances would mean more time to fund development; faster cash use without collaboration revenue keeping pace would leave less room for that trial and other research, increasing financing pressure.
